Downregulation and upregulation

Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL

Retrieved on: 
Monday, December 13, 2021
Therapy, U.S. Securities and Exchange Commission, Regenerative medicine, Cytokine release syndrome, NK, FDA, Graft-versus-host disease, Company, Downregulation and upregulation, Destiny, ADCC, Follicular lymphoma, Aggressive lymphoma, Private Securities Litigation Reform Act, IPSC, Cancer, Review, B-cell lymphoma, Immunotherapy, Risk, Trastuzumab, Canadian Aviation Regulations, Safety, Patient, Cetuximab, BCL, Immunoglobulin G, Cyclophosphamide, Security (finance), Drug development, Patent, Lymphoma, CD16, Program, DL, CRS, Acute myeloid leukemia, Maintenance, CAR, FC, CA, Antibody, Rituximab, Vaccine, Pharmaceutical industry

SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today presented positive clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT516 for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63rd American Society of Hematology Annual Meeting and Exposition. FT516 is the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, which is designed to maximize antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells.

Key Points: 
  • The Company has initiated enrollment in the dose-expansion stage of its Phase 1 study of FT516 in combination with rituximab for the treatment of relapsed / refractory BCL at 900 million cells per dose.
  • In addition, the Company plans to enroll an expansion cohort without conditioning chemotherapy, combining FT516 with rituximab and bendamustine, a standard-of-care treatment regimen for lymphoma.
  • Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body.
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.

Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting

Retrieved on: 
Wednesday, December 8, 2021
FC, Canadian Aviation Regulations, Trastuzumab, Investor, Company, CA, GLOBE, B-cell lymphoma, Immunotherapy, CAR, Lymphoma, NK, Therapy, ADCC, Patient, Downregulation and upregulation, Acute myeloid leukemia, Cancer, Rituximab, Exposition, Antibody, CD16, IPSC, CLL, Maintenance, Chronic lymphocytic leukemia, CD19, Patent, Immunoglobulin G, FDA, NASDAQ, SAN, Society, Cetuximab, Destiny, ASH, Vaccine

The archived webcast will be available on the Company's website beginning approximately two hours after the event.

Key Points: 
  • The archived webcast will be available on the Company's website beginning approximately two hours after the event.
  • The event is not an official program of the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.
  • Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.

F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference

Retrieved on: 
Friday, November 12, 2021
Cancer, Therapy, CD137, Clinical trial, Immunoglobulin G, Society for Immunotherapy of Cancer, Terminology, Securities Exchange Act of 1934, DLBCL, Communication, Biology, PSLRA, Safety, OX40, Bispecific monoclonal antibody, Pharmacology, Technology, Forward-looking statement, Conference, GLOBE, Time, Patent, Patient, D.C, PD-L1, Private Securities Litigation Reform Act, NASDAQ, Society, Pembrolizumab, IO, NSCLC, SEC, Drug discovery, Immunotherapy, Head, SITC, Maintenance, Downregulation and upregulation, Annual report, CNS, Company, Antibody, Toxicity, Nasdaq, Drug development, Pharmaceutical industry, Vaccine

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced that the Company is participating in the 36th annual Society for Immunotherapy of Cancer (SITC) 2021 Conference, taking place November 12-14 in Washington, D.C. F-star’s Michelle Morrow, Ph.D., will speak at 9:15 a.m. on Sunday, November 14, during Session 300: Novel Bispecifics, on “Dual Checkpoint Bispecifics: Next Generation Cancer Therapy to Overcome Immune Evasion”. We are also excited to announce that Matthew Lakins Ph.D., is lead author on poster presentation #573, on preclinical data for FS120 combination with PD-1 [https://investors.f-star.com/static-files/457405c6-e6e0-4dee-9596-2446e2..., a first-in-class dual-agonist tetravalent bispecific antibody targeting OX40 and CD137. FS120 is currently being evaluated in a Phase 1 monotherapy dose escalation clinical trial (NCT04648202) which aims to identify a well-tolerated and pharmacologically active dose of FS120 for exploration in future clinical studies as monotherapy, and in combination with other agents.

Key Points: 
  • F-stars FS118 is a dual checkpoint inhibitor targeting PD-L1 and LAG-3 that drives LAG-3 shedding and receptor down-regulation, via bispecific activity.
  • FS118 is designed to provide unique pharmacology, causing a dose-dependent increase of soluble LAG-3, and potentially offering a more durable response in patients.
  • F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer.
  • Forward-looking statements included in this communication are based on information available to F-star as of the date of this communication.

MiNA Therapeutics Highlights Clinical Data Supporting the Further Development of MTL-CEBPA as an Anti-cancer Immunotherapy

Retrieved on: 
Friday, November 12, 2021
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Clinical Cancer Research, Safety, SITC, Cancer, Health care, Sorafenib, Therapy, Lists of diseases, MHRA, RNA, Myelocyte, Technology, Food, Liver cancer, Trial of the century, Society, Pembrolizumab, MTL, Mina, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hepatocellular carcinoma, Society for Immunotherapy of Cancer, Annual general meeting, Company, Research, Downregulation and upregulation, Data, C/EBP, SaRNA, Immunotherapy, Lung, Mesothelioma, HCC, Cell, Patient, FDA, Adult, Medical imaging, Pharmaceutical industry, the TIMEPOINT study, MTL-CEBPA, MiNA Therapeutics, THE TIMEPOINT STUDY, MTL-CEBPA, MINA THERAPEUTICS

The data will be initially presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place on 10-14 November 2021.

Key Points: 
  • The data will be initially presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place on 10-14 November 2021.
  • Separately, MiNA also highlights the publication of positive data in the peer-reviewed journal Clinical Cancer Research, demonstrating MTL-CEBPAs mechanism of action across different tumour models and in cancer patients.
  • The data presented at SITC and published in Clinical Cancer Research further adds to the strong foundation of clinical evidence we have established for MTLCEBPA.
  • We are excited to progress into Phase 1b the development of MTL-CEBPA in patients with solid tumour malignancies.

Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference

Retrieved on: 
Tuesday, November 9, 2021
Safety, AML, Masonic Cancer Center, SITC, Maintenance, University, Cancer, Private Securities Litigation Reform Act, Therapy, Investor, SAN, Destiny, University of Minnesota, Security (finance), NASDAQ, Acute myeloid leukemia, Downregulation and upregulation, Society, CA, NK, Immunotherapy, CAR, CD16, ID, Daratumumab, Multiple myeloma, Society for Immunotherapy of Cancer, Conference, U.S. Securities and Exchange Commission, GLOBE, Canadian Aviation Regulations, Antibody, Oxidative stress, Environment and Communications Committee (Iceland), IPSC, Survival, Patent, Patient, Cell Stem Cell, Risk, CD38, Pharmaceutical industry, Vaccine

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Society for Immunotherapy of Cancer (SITC) Communications Committee selected an abstract featuring preclinical data from the Company’s FT538 and FT573 programs for showcase at the SITC 2021 Annual Meeting Press Conference. The selected abstract entitled “Off-the-shelf, engineered iPSC-derived NK cells mediate potent cytotoxic activity against primary glioblastoma cells and promote durable long-term survival in vivo” will be presented by Jeffrey S. Miller, M.D., Professor of Medicine, University of Minnesota and Deputy Director, Masonic Cancer Center. The press conference is being held on Wednesday, November 10 from 12:30-2 pm ET.

Key Points: 
  • The published data demonstrate that FT538 exhibits significantly enhanced serial killing and functional persistence compared to peripheral blood NK cells.
  • ET to highlight its emerging pipeline of off-the-shelf, multiplexed-engineered, iPSC-derived NK cell programs for the treatment of solid tumors.
  • In order to participate in the conference call, please dial (877) 303-6235 (domestic) or (631) 291-4837 (international) and refer to conference ID 2793475.
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.

Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting

Retrieved on: 
Thursday, November 4, 2021
Safety, B-cell lymphoma, Immunotherapy, FC, Neoplasm, CAR, U.S. Securities and Exchange Commission, Graft-versus-host disease, ASH, Maintenance, IPSC, Lymphoma, Lymphoid leukemia, BCMA, Therapy, Cancer immunotherapy, GLOBE, Downregulation and upregulation, Leukemia, Poster, GVHD, Security (finance), PET-CT, Private Securities Litigation Reform Act, Acute lymphoblastic leukemia, Company, Acute leukemia, Bone marrow, CLL, Rituximab, Cytokine release syndrome, CD19, SAN, Cetuximab, CA, TRAC, Canadian Aviation Regulations, Antibody, Risk, CD16, Trastuzumab, Society, B-cell maturation antigen, Cancer, Immunoglobulin G, CRS, ADCC, NASDAQ, FDA, Efficacy, Patent, TCR, NK, Acute myeloid leukemia, Chronic lymphocytic leukemia, Destiny, Multiple myeloma, Vaccine, Pharmaceutical industry

SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that three oral and five poster presentations for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition being held from December 11-14, 2021. The Company also plans to host a virtual investor event on Tuesday, December 14.

Key Points: 
  • The Company previously reported interim Phase 1 clinical data of FT516 in combination with rituximab for the treatment of relapsed / refractory B-cell lymphoma.
  • The multi-dose, multi-cycle treatment regimen was well tolerated, and no adverse events of CRS, ICANS, or GVHD were reported.
  • Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.

Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support

Retrieved on: 
Wednesday, September 15, 2021
Immunotherapy, U.S. Securities and Exchange Commission, Security (finance), Therapy, HER2, SAN, Canadian Aviation Regulations, University, CA, Oxidative stress, AML, EGFR, Antibody, Protein, Cell Stem Cell, Patient, CD16, Cytomegalovirus, Daratumumab, Company, Private Securities Litigation Reform Act, Patent, Risk, NK, Safety, Destiny, Development, NASDAQ, Acute myeloid leukemia, IPSC, Miller, Downregulation and upregulation, ATP, University of Minnesota, GLOBE, CD38, Glycolysis, Cancer, Multiple myeloma, Maintenance, Vaccine, Pharmaceutical industry

The NK cell community has long sought to improve NK cell activation, cytotoxicity, functional persistence, and tumor targeting for cancer immunotherapy.

Key Points: 
  • The NK cell community has long sought to improve NK cell activation, cytotoxicity, functional persistence, and tumor targeting for cancer immunotherapy.
  • Our preclinical data demonstrate that the synthetic features of FT538 uniquely harness all these therapeutic attributes and significantly improve NK cell anti-tumor activity, said Bob Valamehr, Ph.D., Chief Research and Development Officer of Fate Therapeutics.
  • The peer-reviewed paper describes preclinical studies showing that FT538 shares metabolic, transcriptional, and functional features with adaptive NK cells.
  • Additionally, in sequential killing assays, FT538 was shown to have robust serial killing and functional persistence, which were not observed with peripheral blood NK cells.

NantHealth and NantOmics to Present Data on Tumor Mutation Burden (TMB) and PD-L1 Expression in SDH/FH Mutated Solid Tumors at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

Retrieved on: 
Monday, June 3, 2019
Health, Biotechnology, Genetics, Oncology, Research, Science, Branches of biology, Biology, Succinate dehydrogenase, Succinic acid, Hypoxia-inducible factors, Fumarase, Pseudohypoxia, Downregulation and upregulation, SDH

Our analysis provides actionable insight and evidence-based support to further our mission of optimizing patient outcomes and enabling value-based care, specifically in the oncology realm.

Key Points: 
  • Our analysis provides actionable insight and evidence-based support to further our mission of optimizing patient outcomes and enabling value-based care, specifically in the oncology realm.
  • Succinate Dehydrogenases and Fumarate Hydratase (SDH/FH) deficient tumors are characterized by succinate/fumarate accumulation and resultant pseudohypoxia that drives malignant transformation.
  • It has been recently shown that HIF-1a stabilization due to hypoxia can lead to upregulation of PD-1 ligand.
  • Retrospective analysis was performed on 3,461 paired tumor/normal whole exome sequences (WES; ~150x coverage) from the NantHealth clinical cases database.